Xvivo Perfusion AB (publ) (0RKL.L) LSE

Currency In SEK

AD

Valuation

Market Cap5.82B
Enterprise Value5.76B
P/E Ratio50.37
PEG Ratio0.15
Price/Sales Ratio6.77
Price/Book Ratio2.86
Enterprise/Revenue6.57
Enterprise/EBITDA29.41

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterSeptember 30, 2026

Profitability

Profit Margin0.13
Operating Margin0.13
AD

Management Effectiveness

Return On Assets0.05
Return On Equity0.06

Income Statement

Revenue812.17M
Revenue/Share30.43
Gross Profit533.5M
EBITDA153.14M
Net Income25.16M
Diluted EPS0.8

Balance Sheet

Total Cash313.24M
Total Cash/Share9.94
Total Debt120.61M
Total Debt/Equity0.05
Current Ratio3.91
Book Value Per Share71.93

Price History

52-Week Change22.45
52-Week High314
52-Week Low162.4
Moving Average 50 Days227.12
Moving Average 200 Days243.7

Statistics

Average Volume7,100
Shares Outstanding31.5M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD